Vincent K. Y. Ho

Vincent K. Y. Ho

Auto-generated profile, based on publicly available information

Vincent K. Y. Ho

Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
VHVincent K.Y. Ho
Vincent K.Y. Ho
JRJaap C. Reijneveld
Jaap C. Reijneveld
RERoelien H. Enting
Roelien H. Enting
HBHenri P. Bienfait
Henri P. Bienfait
PRPierre Robe
Pierre Robe
OVOtto Visser
Otto Visser

1 September 2018 in Surgical Oncology
Verified
Journal Article
Open access
VPVeroniek Muriël Van Praag
Veroniek Muriël Van Praag
ARA.J. Rueten-Budde
A.J. Rueten-Budde
VHV. Ho
V. Ho
PDP.D.S. Dijkstra
P.D.S. Dijkstra
MFMarta Fiocco
Marta Fiocco
JPJoris Jan Willem Ploegmakers
Joris Jan Willem Ploegmakers
There are few studies detailing the incidence, patient outcomes and prognostic factors for chondrosarcomas (CS). Those that do exist have small sample sizes and/or use older datasets. The purpose of this study was to determine the incidence, overall survival (OS) and prognostic factors for OS of CS patients, as well as investigate the efficacy of curettage. We analyzed data of 2186 patients diagnosed with chondrosarcomas between '89-'13 from the Netherlands Cancer Registry. The effect of risk factors on OS was assessed with a multivariate Cox regression. Median Follow-up was determined with reversed Kaplan-Meier. OS was estimated using Kaplan-Meier method. The relative incidence of CS was 2.88 per million citizens between '89-'96, 4.15 between '96-'04 and 8.78 between '05-'13. Most of the increase in incidence came from atypical cartilaginous tumours/grade I chondrosarcoma (ACT/CS I). The 3-, 5- and 10-years survival were, respectively, 96%, 93% and 88% for ACT/CS I, 82%, 74% and 62% for grade II CS and 38%, 31% and 26% for grade III CS. Prognostics factors significantly associated with OS were age, histological grade, year of diagnosis, tumour location and size. The incidence of CS, and especially ACT/CS I, has increased over time, which could be driven by both an ageing population and increased diagnostic imaging. With the increased number of diagnosed ACT/CS I, the number of preventative curettages of this tumour has also increased. Despite the supposed preventative character of this treatment, the incidence of high-grade CS did not decrease.

8 March 2016 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MHMiriam L. Hoven-Gondrie
Miriam L. Hoven-Gondrie
EBEsther Bastiaannet
Esther Bastiaannet
VHVincent K.Y. Ho
Vincent K.Y. Ho
BLBarbara L. Van Leeuwen
Barbara L. Van Leeuwen
GLGerrit-Jan Liefers
Gerrit-Jan Liefers
ASAlbert J. H. Suurmeijer
Albert J. H. Suurmeijer
Nearly half of soft-tissue sarcoma (STS) patients are over the age of 65, and the behavior of cancer in these elderly patients is poorly understood. The ai

1 October 2018 in Cancer Epidemiology
Verified
Journal Article
Closed access
CSCharles Stiller
Charles Stiller
LBLaura Botta
Laura Botta
DBDavid H. Brewster
David H. Brewster
VHVincent K.Y. Ho
Vincent K.Y. Ho
AFAnna Maria Frezza
Anna Maria Frezza
Gemma GattaGemma Gatta
Gemma Gatta


22 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CHChiel van der Horst
Chiel van der Horst
SBSabien L. M. Bongers
Sabien L. M. Bongers
YVYvonne MH Versleijen-Jonkers
Yvonne MH Versleijen-Jonkers
VHVincent K. Y. Ho
Vincent K. Y. Ho
PBPètra M. Braam
Pètra M. Braam
IDIngrid M.E. Desar
Ingrid M.E. Desar
Myxofibrosarcoma (MFS) is a rare mesenchymal soft tissue sarcoma type, with a high local recurrence (LR) rate. Robust epidemiological data on MFS are lacking. We, therefore, aimed to identify prognostic factors and describe real-life outcomes of a large cohort of 908 MFS patients obtained from the nationwide database of the Netherlands Cancer Registry and diagnosed between 2002 and 2019. Median Overall survival (OS) was 155 (range 0.1–215) months, with a five-year OS of 67.7%. No improvement of OS was found over time. Multivariable Cox regression survival analysis demonstrated known prognostic factors for OS, such as older age, tumour size, and histological grade with the addition of sex. Surgery at sarcoma expertise centres, instead of general hospitals, was associated with better OS outcomes. In a subcohort of 177 patients, 39% developed LR with a median time to recurrence of 20 months. From LR on, the median OS was 64.0 months (CI 95% 38.5–89.5). In 28%, distant metastases were diagnosed with a median OS of 34.3 months (CI 95% 28.8–39.8) after diagnosis of the primary tumour. In this largest nationwide cohort so far, survival outcomes and recurrence rates for MFS patients did not improve over time, emphasizing the need to improve treatment strategies and suggesting a role for sarcoma expertise centres.